Redeye
SE - Stockholm - Stockholm County
About Redeye
redeye is the next generation equity research and investment banking company, specialized in life science and technology. we are the leading provider of corporate broking and corpora... Read more
Website:
redeye.se
Industry:
finance
Phone number:
+46 8 545 013 30
Employees:
51-200 employees View all employees
Founded:
Last updated:
Email:
Total Emails: 112 Total email addresses we have for one domain. View all emails
Total personal emails: 109 Total personal emails we have for one domain. View all emails
Total generic emails: 3 Total generic emails we have for one domain. View all emails
Whois Info:
Whois Name: Ports Group AB
Creation Date: March 15th 2000, 12:00:00 am
Domain search & Email Finder Tool
The Domain Search allows to find emails from a domain, or website.
Give it a shot. Find 10 email addresses for free!
Email Sources
Emails publicly sourced from the internet using the TombaWebPublic crawler.
Total sources 154
URL | Extracted on |
---|---|
https://pdfslide.net/documents/life-scie.. | |
https://fdocuments.net/document/life-sci.. | |
https://www.mynewsdesk.com/se/redeye/pre.. | |
https://www.mynewsdesk.com/se/redeye/pre.. | |
https://www.mynewsdesk.com/se/redeye/pre.. | |
https://www.skymem.info/srch?q=redeye.se.. | |
https://www.mynewsdesk.com/se/redeye/pre.. | |
https://www.mynewsdesk.com/se/redeye/pre.. | |
https://www.mynewsdesk.com/se/redeye/pre.. | |
https://www.paynova.com/en-us/investors/.. | |
https://www.paynova.com/sv-se/investerar.. | |
https://pdfslide.net/documents/redeye-on.. | |
https://pdfslide.net/documents/gaming-in.. | |
https://pdfslide.net/documents/gaming-in.. | |
https://arocell.com/arocell-company-over.. | |
https://arocell.com/sv/arocell-en-samman.. | |
https://pdfslide.net/documents/initiatio.. | |
https://pdfslide.net/documents/rls-globa.. | |
https://pdfslide.net/documents/episurf-m.. | |
https://r.cnpmjs.org/@rdey/collapse-button | |
https://r.cnpmjs.org/@rdey/components | |
https://r.cnpmjs.org/@rdey/design | |
https://pdfslide.net/documents/initiatio.. | |
https://pdfslide.net/documents/initiatio.. | |
https://pdfslide.net/documents/enea-amaz.. | |
https://documents.pub/document/initiatio.. | |
https://fdocuments.net/document/initiati.. | |
https://www.ascelia.com/sv/aktieanalyser/ | |
https://xspraypharma.com/investerare/akt.. | |
https://xspraypharma.com/en/investors/sh.. | |
https://pdfslide.net/documents/blockbust.. | |
https://pdfslide.net/documents/callidita.. | |
https://www.axichem.com/investors-relati.. | |
https://pdfslide.net/documents/tagmaster.. | |
https://pdfslide.net/documents/i-tech-de.. | |
https://pdfslide.net/documents/mytaste-g.. | |
https://documents.pub/document/mytaste-g.. | |
https://www.mynewsdesk.com/se/redeye/pre.. | |
https://www.mynewsdesk.com/se/redeye/pre.. | |
https://pdfslide.net/documents/redeye-on.. | |
https://fdocuments.net/document/redeye-o.. | |
https://www.powercell.se/en/investors/an.. | |
https://www.catella.com/sv/investor-rela.. | |
https://www.beijergroup.com/en/Corporate.. | |
https://www.catella.com/en/investor-rela.. | |
https://pdfslide.net/documents/initiatio.. | |
https://www.mynewsdesk.com/se/ig/pressre.. | |
https://www.cellavision.com/en/for-inves.. | |
https://www.cellavision.com/en/for-inves.. | |
https://www.cellavision.com/en/for-inves.. | |
https://pdfslide.net/documents/clinical-.. | |
https://pdfslide.net/documents/rls-globa.. | |
https://www.mynewsdesk.com/se/redeye/pre.. | |
https://www.mynewsdesk.com/se/redeye/pre.. | |
https://pdfslide.net/documents/acconeer-.. | |
https://pdfslide.net/documents/acconeer-.. | |
https://documents.pub/document/acconeer-.. | |
https://www.mynewsdesk.com/se/redeye/pre.. | |
https://www.mynewsdesk.com/se/redeye/pre.. | |
https://www.mynewsdesk.com/se/redeye/pre.. | |
https://pdfslide.net/documents/redeye-on.. | |
https://www.skymem.info/srch?q=redeye.se.. | |
https://www.mynewsdesk.com/se/redeye/pre.. | |
https://speqta.com/investors/analyst-cov.. | |
https://speqta.com/en/investors/analyst-.. | |
https://pdfslide.net/documents/initiatin.. | |
https://pdfslide.net/documents/initiatin.. | |
https://pdfslide.net/documents/nordic-sa.. | |
https://pdfslide.net/documents/a1m-pharm.. | |
https://documents.pub/document/a1m-pharm.. | |
https://fdocuments.net/document/a1m-phar.. | |
https://pdfslide.net/documents/xvivo-per.. | |
https://fdocuments.net/document/xvivo-pe.. | |
https://www.investors.artificial-solutio.. | |
https://www.investors.artificial-solutio.. | |
https://www.investors.artificial-solutio.. | |
https://pdfslide.net/documents/callidita.. | |
https://fdocuments.net/document/callidit.. | |
https://immunicum.se/investors/analyst-c.. | |
https://pdfslide.net/documents/alzinova-.. | |
https://pdfslide.net/documents/bioinvent.. | |
https://pdfslide.net/documents/cantargia.. | |
https://www.skymem.info/srch?q=redeye.se.. | |
https://www.mynewsdesk.com/se/redeye/eve.. | |
https://www.mobergpharma.com/investors/a.. | |
https://pdfslide.net/documents/optomed-a.. | |
https://pdfslide.net/documents/saniona-s.. | |
https://fdocuments.net/document/saniona-.. | |
https://www.mynewsdesk.com/se/redeye/pre.. | |
https://www.mynewsdesk.com/se/redeye/pre.. | |
https://www.mynewsdesk.com/se/redeye/pre.. | |
https://www.mynewsdesk.com/se/redeye/pre.. | |
https://pdfslide.net/documents/genovis-a.. | |
https://fdocuments.net/document/genovis-.. | |
https://www.mynewsdesk.com/se/redeye/pre.. | |
https://www.mynewsdesk.com/se/redeye/pre.. | |
https://www.mynewsdesk.com/se/redeye/pre.. | |
https://www.mynewsdesk.com/se/redeye/pre.. | |
https://www.mynewsdesk.com/se/redeye/pre.. | |
https://www.mynewsdesk.com/se/redeye/pre.. | |
https://www.mynewsdesk.com/se/redeye/doc.. | |
https://www.mynewsdesk.com/se/redeye/doc.. | |
https://www.mynewsdesk.com/se/redeye/doc.. | |
https://nanexa.com/analytiker/ | |
https://www.mynewsdesk.com/se/redeye/pre.. | |
https://pdfslide.net/documents/new-co-pi.. | |
https://fdocuments.net/document/new-co-p.. | |
https://www.mynewsdesk.com/se/redeye/new.. | |
https://www.mynewsdesk.com/se/redeye/pre.. | |
https://www.mynewsdesk.com/se/redeye/pre.. | |
https://www.mynewsdesk.com/se/guventures.. | |
https://www.mynewsdesk.com/se/guventures.. | |
https://www.mynewsdesk.com/se/guventures.. | |
https://www.benzinga.com/pressreleases/2.. | |
https://www.mynewsdesk.com/se/redeye/pre.. | |
https://www.mynewsdesk.com/se/redeye/pre.. | |
https://www.mynewsdesk.com/se/redeye/pre.. | |
https://pdfslide.net/documents/redeye-on.. | |
https://www.investors.artificial-solutio.. | |
https://www.investors.artificial-solutio.. | |
https://www.mynewsdesk.com/se/redeye/pre.. | |
https://www.mynewsdesk.com/se/redeye/pre.. | |
https://www.mynewsdesk.com/se/redeye/pre.. | |
https://pdfslide.net/documents/initiatin.. | |
https://pdfslide.net/documents/initiatin.. | |
https://pdfslide.net/documents/cimco-mar.. | |
https://fdocuments.net/document/cimco-ma.. | |
https://www.mynewsdesk.com/se/redeye/pre.. | |
https://www.mynewsdesk.com/se/redeye/pre.. | |
https://www.mynewsdesk.com/se/redeye/pre.. | |
https://www.annexinpharma.com/en/analyst.. | |
https://www.irlab.se/investor-relations/.. | |
https://www.alzinova.com/investors/the-s.. | |
https://asarinapharma.com/investors/the-.. | |
https://www.mynewsdesk.com/se/redeye/pre.. | |
https://www.enea.com/investors/the-enea-.. | |
https://www.mynewsdesk.com/se/tele_5_ab_.. | |
https://www.indexpharma.com/sv/investera.. | |
https://bioinvent.se/investerare/kalende.. | |
https://immunicum.se/investors/analyst-c.. | |
https://immunicum.se/investerare-se/anal.. | |
https://isofolmedical.com/analysts/ | |
https://pdfslide.net/documents/divitum-t.. | |
https://www.redeye.se/faq | |
https://www.mynewsdesk.com/se/redeye/pre.. | |
https://www.mynewsdesk.com/se/redeye/pre.. | |
https://player.fm/series/investing-by-th.. | |
https://www.beijergroup.com/en/Corporate.. | |
https://embracer.com/investors/the-share.. | |
https://embracer.com/investors/the-share.. | |
https://investors.remedygames.com/analys.. | |
https://www.mynewsdesk.com/se/redeye/pre.. | |
https://www.mynewsdesk.com/se/redeye/pre.. | |
https://worldsitelink.com/email_by_domai.. |
Company Leadership
Eddie Palmgrenchief editor
Thomas Nybergfounder insightlab
Bjorn FahlenCEO
Employee Directory
Palin Palinklas
Johan Nilsson
Erik Krammingcorporate advisory
Viktoria RinaldoProject Manager Event
Jonas Amnesten
With Tomba you can find and verify Redeye's email formats
For 112 verified Redeye Employees Email